A groundbreaking investigation originating from Brazil has provided critical insights into the insidious mechanisms by which pancreatic cancer orchestrates its early dissemination throughout the body. Published in the esteemed journal Molecular and Cellular Endocrinology, the research meticulously details how a specific protein, periostin, in concert with specialized pancreatic stellate cells, fundamentally contributes to the invasive capacity of tumor cells into surrounding nerve structures. This early cellular infiltration along neural pathways is a recognized harbinger of aggressive disease progression and significantly escalates the probability of metastasis, the spread of cancer to distant organs. The revelations from this study not only deepen our understanding of this particularly lethal malignancy but also pinpoint novel molecular targets for the development of more precise and individualized therapeutic strategies.
Pancreatic cancer, predominantly pancreatic ductal adenocarcinoma (PDAC), stands as one of the most formidable challenges in oncology. Despite not being among the most frequently diagnosed cancers, its high mortality rate nearly mirrors its incidence, making it a leading cause of cancer-related deaths globally. Annually, approximately 510,000 new cases are reported worldwide, with a tragic number of nearly identical fatalities. In Brazil, national estimates from the National Cancer Institute (INCA) indicate around 11,000 new diagnoses and 13,000 deaths each year. Oncologist Pedro Luiz Serrano Uson Junior, a co-author of the study, underscores the grim reality: "It’s an aggressive cancer that’s difficult to treat. Around 10% of patients have a chance of long-term survival, such as five years after diagnosis." This stark prognosis is largely attributable to the disease’s silent progression, often presenting with non-specific symptoms only in advanced stages, and its inherent resistance to conventional treatments.
A critical characteristic contributing to the extreme danger of pancreatic cancer is a phenomenon termed perineural invasion (PNI). This pathological process describes the direct infiltration and subsequent migration of cancer cells along the sheaths of nerves. PNI is not merely a marker of advanced disease; it actively facilitates metastatic spread by providing protected conduits for tumor cells to escape the primary site. Furthermore, the invasion of nerves by cancer cells is a significant contributor to the severe, often intractable pain experienced by patients with pancreatic cancer. As Uson explains, "Perineural invasion is a marker of cancer aggressiveness." The neural network, extending throughout the body, effectively transforms into a biological highway system for disseminating malignant cells, granting them access to various anatomical regions and fostering the development of secondary tumors.
The recent Brazilian study illuminates how pancreatic tumors do not merely proliferate in isolation but rather actively sculpt and manipulate their immediate surroundings – known as the tumor microenvironment (TME). This complex ecosystem, comprising stromal cells, immune cells, blood vessels, and the extracellular matrix (ECM), is effectively reprogrammed by the malignant cells to support their growth, survival, and invasive potential. This intricate crosstalk between cancer cells and their microenvironment helps to explain why PDAC is so notoriously difficult to manage once it begins its relentless spread. Understanding this dynamic interplay is crucial, as the TME often creates a physical and immunological barrier that impedes the efficacy of therapeutic agents.
The sophisticated research was conducted at the Center for Research on Inflammatory Diseases (CRID), one of FAPESP’s Research, Innovation, and Dissemination Centers (RIDCs), underscoring the collaborative and well-funded scientific ecosystem driving advanced medical discoveries. The investigation was spearheaded by researcher Carlos Alberto de Carvalho Fraga, with Professor Helder Nakaya, a senior researcher at Einstein Israelite Hospital and a faculty member at the University of São Paulo’s School of Pharmaceutical Sciences, serving as the principal investigator. To meticulously unravel the elusive mechanisms underlying nerve invasion, the team employed cutting-edge methodologies. These included advanced spatial transcriptomics and single-cell sequencing techniques, which allowed them to analyze the transcriptional activity of thousands of genes within individual cells while precisely mapping their spatial coordinates within the complex architecture of tumor tissue. Nakaya emphasized the unprecedented resolution achieved, stating, "We were able to integrate data from dozens of samples with extremely powerful resolution."
By examining 24 pancreatic cancer tissue samples, the researchers confirmed a pivotal paradigm shift in cancer biology: the stroma, once considered a mere supportive scaffolding, actively participates in and promotes cancer progression. Far from being a passive structural element, this connective tissue, rich in various cell types and ECM components, dynamically interacts with tumor cells, influencing their behavior and fate. This active role of the stroma, particularly in the context of desmoplasia, is increasingly recognized as a major driver of therapeutic resistance and metastatic potential in PDAC.
A cornerstone discovery of the study involved the heightened production of periostin by activated pancreatic stellate cells (PSCs). Periostin is a matricellular protein, meaning it interacts with both cells and the extracellular matrix, playing diverse roles in tissue development, wound healing, and disease processes. In the context of cancer, periostin is known for its profound ability to remodel the extracellular matrix—the intricate network of macromolecules that provides structural and biochemical support to surrounding cells. The normal ECM maintains tissue homeostasis and acts as a barrier, but in cancer, it undergoes significant pathological restructuring.
Tumor cells exploit these major alterations to the ECM, which involve the degradation of existing components and the deposition of new ones, to facilitate their movement and push through tissue barriers to reach adjacent nerves. This extensive remodeling process is orchestrated by various specialized enzymes, such as matrix metalloproteinases (MMPs), and leads to widespread disruption of normal tissue architecture. As Nakaya elucidated, "Periostin participates in this remodeling, paving the way for tumor cells to invade." Once cancer cells successfully breach and enter a nerve, this neural conduit essentially transforms into a protected "road" or "highway," providing a direct and efficient route for them to spread further into the body, evading immune surveillance and drug delivery.
The transformation of the tumor microenvironment often culminates in a pronounced desmoplastic reaction. This pathological response is characterized by the excessive accumulation of dense, fibrous connective tissue around the tumor. This fibrotic stroma is composed of an abundance of activated PSCs (myofibroblast-like cells), collagen fibers, and other ECM proteins, creating a stiff, hypoxic, and often inflamed milieu. This hardened, desmoplastic tissue poses a formidable physical barrier that severely restricts the penetration of chemotherapy agents and even advanced immunotherapy drugs into the core of the tumor. Consequently, this protective microenvironment allows cancer cells to evade therapeutic assault, survive, and continue their relentless proliferation and dissemination. "That’s why pancreatic cancer is still so difficult to treat," Uson emphasizes, highlighting the clinical ramifications of this stromal fortress.
The tumor’s acquired ability to infiltrate surrounding tissues, particularly nerves, is a primary factor contributing to the dismal prognosis for many pancreatic cancer patients. Uson reiterates that "perineural invasion is a sign that cancer cells have gained mobility. They escape the tumor mass, travel through healthy tissue, and reach nerve and lymphatic bundles, which carry them to other regions of the body, facilitating the development of metastases." Alarmingly, more than half of all pancreatic cancer cases exhibit evidence of perineural invasion even at an early stage. However, this critical indicator of aggressive disease is typically only discovered retrospectively during histopathological examination of the surgical specimen after a pancreatectomy. "Unfortunately, we discover this perineural invasion after it’s already occurred. It’s only seen in the surgical specimen when it goes for biopsy," Uson notes, underscoring the current diagnostic limitations and the urgent need for pre-operative markers.
In light of these formidable challenges, the researchers posit that periostin represents a highly promising therapeutic target for future interventions. Strategies aimed at reducing its activity or selectively eliminating the activated stellate cells responsible for its production could potentially limit nerve invasion and significantly impede the cancer’s metastatic capacity. "This work points to paths that may guide future approaches to treating pancreatic cancer," Nakaya states, expressing optimism for translational impact. Encouragingly, clinical trials are already underway in other cancer types, evaluating the efficacy of monoclonal antibodies specifically designed to block periostin. Nakaya suggests that the outcomes from these trials could inform whether a similar strategy might prove effective in the context of pancreatic cancer.
Uson further elaborates that this targeted approach aligns seamlessly with the evolving paradigm of precision medicine. "If we can develop antibodies or drugs that block these stellate cells, we’ll have tools to prevent the tumor from acquiring this invasive capacity so early." He highlights the current absence of specific treatments directly addressing perineural invasion, suggesting that such therapies could also yield benefits for patients battling other malignancies known for PNI, including certain intestinal and breast cancers. Beyond the identification of novel therapeutic targets, the study also exemplifies the transformative power of advanced data analysis, particularly the judicious leveraging of publicly available genomic and proteomic databases. "We were able to ask and answer new questions that the original authors hadn’t considered," Nakaya remarks, showcasing the potential for re-analysis of existing data to generate new hypotheses.
The immediate subsequent phase of research, according to the scientific team, involves translating these fundamental biological insights into tangible clinical interventions that can act pre-emptively, before invasion becomes firmly established. Uson concludes with a forward-looking perspective on oncology: "Precision medicine is advancing. In the future, we’ll treat patients based on genomic and molecular changes rather than tumor type specifically. This is a significant advance in oncology." The ultimate goal is to shift from reactive treatments of established disease to proactive interventions that prevent the earliest steps of metastatic dissemination, fundamentally altering the prognosis for patients facing pancreatic cancer.
About the Author
